Harmony Biosciences Holdings, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Harmony Biosciences Holdings, Inc. | HRMY - NASDAQ |
$20.00-$23.00 | $24.00 | $39.99 | 5.3 million | 8/19/2020 |
| Goldman Sachs, Jefferies, Piper Sandler | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-07-27 Terms Added 2020-08-11 | ||||||
Harmony Biosciences Holdings, Inc. Quote & Chart - Click for current quote - HRMY
IPO Boutique aggregates information on public companies and private companies, such as "HRMY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Harmony Biosciences Holdings, Inc. (adapted from Harmony Biosciences Holdings, Inc. prospectus):
They are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "HRMY" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.